The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
Patient older than 18 years
Diagnosis of advanced/metastatic Renal Cell Carcinoma (RCC) with a clear-cell component
No prior systemic treatment for RCC
Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, in first line for advanced/metastatic RCC, according to approved local labels
Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Current participation in another clinical study and/or in an investigational program with any intervention that could possibly interfere with the treatment and impact this study
Patient with history of allergy or hypersensitivity to components of the study drugs
Patient with contraindication to the study drugs